Status: Not yet recruiting
A Study of DA-302168S in Participants With Overweight/Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.
Participants needed: 840
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Chendu DIAO Pharmaceutical Group CO., LTD.Updated: Jun 5, 2026Locations: 1
Eligibility criteria
Age 18-75 years (inclusive), both males and females; [+2]
Type 1 diabetes, type 2 diabetes, or other specific types of diabetes (excluding... [+9]